CAMBRIDGE, Mass.--(BUSINESS WIRE)--Suono Bio, a biotechnology company focused on enabling ultra-rapid and formulation-independent delivery of biologics and nucleic acids, announced today the addition of Lisa Ricciardi and appointment as CEO effective September 1.
“The addition of Lisa to the team marks an important milestone for Suono Bio, particularly as we prepare for our entry to the clinic,” said Dr. Carl Schoellhammer, the founding CEO who will assume the position of COO and board member. “The company is well poised to accelerate its activities under her leadership and I am delighted to have her join the team.”
The addition of senior leadership comes at an exciting time for Suono Bio, which today also announced a strategic investment by Fujifilm Corporation to help expand its pipeline of therapeutic products. Suono Bio leverages technology developed in the laboratory of Institute Professor Robert Langer at the Massachusetts Institute of Technology (MIT) to facilitate rapid, local administration of therapeutics to treat serious diseases. The company has demonstrated pre-clinical activity in a range of diseases using a diverse set of therapeutics, including genetic material and proteins, at clinically-relevant doses. The company was founded by Professor Langer, Dr. Giovanni Traverso, a gastroenterologist and biomedical engineer at Brigham and Women’s Hospital, Harvard Medical School, Amy Schulman, partner at Polaris Partners and executive chair of Suono Bio, and Dr. Schoellhammer.
“Lisa brings a tremendous breadth of leadership experience that, combined with Carl’s thoughtful and strategic execution and start of our relationship with Fujifilm, will expedite the company’s programs to bring novel therapies to patients suffering from diseases with high unmet need,” added Schulman.
Over her career, Ricciardi has worked for top pharmaceutical, payer, and molecular diagnostics firms including Pfizer, Medco, and Foundation Medicine, and Essex Woodlands VC in strategic, transactional, and operating roles, including multiple product launches. She is currently a Director of UDG Healthcare plc and an advisor to Humania Capital, a Dubai-based private equity group.
“The team has executed a strategy designed to get to the clinic quickly and efficiently and demonstrate the technology’s impact,” said Ricciardi. “I am pleased to join the Suono Bio team and bring forward a transformational program with broad clinical application.”
ABOUT SUONO BIO
Suono Bio is developing therapeutic products for inflammatory-mediated diseases leveraging their ultra-rapid and formulation independent delivery technology. Suono Bio’s platform enables rapid, localized delivery of small molecules, biologics, and nucleic acids and gene therapies without the need for encapsulation of the therapeutic. For more information, please visit www.suonobio.com.